Genetic marker for drug risk in multiple sclerosis offers path toward precision medicine

July 16, 2018, University of British Columbia
Demyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100. Credit: Marvin 101/Wikipedia

A team of researchers has uncovered a specific gene variant associated with an adverse drug reaction resulting in liver injury in a people with multiple sclerosis (MS). It is the first time researchers have been able to establish a validated genetic marker for a drug-induced harm in people with MS.

Published July 16 in the journal Nature Genetics, the findings inform a broader understanding of genetic risk of drug reactions in MS and may lead to clinically useful tests for more individualized approaches to MS treatment and care.

MS rates in Canada are the highest in the world, and the disease affects an estimated 100,000 Canadians. Most people diagnosed with MS are young adults between the ages of 15 and 40 but the disease can also be diagnosed in young children and older adults. MS results from the body's immune system attacking myelin, the fatty material that insulates neurons and enables rapid transmission of electrical signals. When myelin is damaged, communication between the brain and other parts of the body is disrupted, leading to vision problems, muscle weakness, difficulty with balance and coordination, and cognitive impairments.

"One in 50 people with MS who are treated with interferon-beta, one of the most commonly prescribed MS therapies, will develop abnormally high levels of ," said Dr. Kaarina Kowalec, a Marie Curie postdoctoral fellow at Sweden's Karolinska Institute and co-lead author of the new study.

Liver injury is a common side effect of many drugs, but this is the first time researchers have connected a with a biologic drug and elevated risk of liver injury. Currently people with MS have their blood monitored for increased liver enzymes, which can indicate potential injury.

Dr. Kowalec conducted her Ph.D. research at the University of British Columbia under the supervision of Dr. Helen Tremlett at the Djavad Mowafaghian Centre for Brain Health and Dr. Bruce Carleton at BC Children's Hospital.

"Risk of liver injury increases eight fold with this marker. It's important that we be able to understand who might be most at risk so that we can intervene with an altered treatment plan or increased monitoring to prevent damage," said Dr. Carleton.

Interferon-beta is a first-generation MS drug that is prescribed to treat the relapse-remitting form of the disease. The works with an individual's own interferons—naturally occurring molecules—that exist in the body to reduce inflammation.

"There's a lot of talk about precision medicine, and whether it can work as well as we hope," said Dr. Kowalec. "Pharmacogenomic testing is a big part of that and we're showing that it is possible. It's something that's been done outside for cancer therapies but now we've shown that there's potential for precision medicine in MS as well."

"We often can't determine a person's individual risk for a future adverse drug event very well; that was the case for in MS, until now," said Dr. Tremlett. "We achieved this by looking for genetic markers. Many were skeptical we would find anything, but we did, and part of what we've done here is set out the methods for other researchers to pursue a similar line of work with the other drugs for MS."

"With more therapeutic options for multiple sclerosis becoming available, identifying predictive biomarkers for safety is of increasing importance," said Dr. Galen Wright, co-first author and postdoctoral researcher in Dr. Michael Hayden's lab at the Centre for Molecular Medicine & Therapeutics at UBC. "As highlighted by the findings of our study, genomics can play a leading role in this regard."

The genetic marker was identified with the help of 150 patients from five Canadian clinics and then validated in 120 patients from three sites in the U.S. and one in Sweden.

"This is the kind of research that makes drugs safer," said Dr. Kowalec. "We are now looking at newer MS drugs and taking a similar approach so that one day, genetic risk may factor into how we diagnose, treat and monitor people with MS in Canada and around the world."

Explore further: A constellation of symptoms presages first definitive signs of multiple sclerosis

More information: Kaarina Kowalec et al, Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis, Nature Genetics (2018). DOI: 10.1038/s41588-018-0168-y

Related Stories

A constellation of symptoms presages first definitive signs of multiple sclerosis

July 16, 2018
During the five years before people develop the first clinically recognized signs of multiple sclerosis (MS), they are up to four times more likely to be treated for nervous system disorders such as pain or sleep problems, ...

Use of MS drug expanded to include children

May 14, 2018
(HealthDay)—The U.S. Food and Drug Administration has expanded its approval of the multiple sclerosis drug Gilenya (fingolimod) to include children aged 10 and older.

Researchers uncover potential risks of common MS treatment

May 15, 2017
In one of the most comprehensive studies to date, UBC researchers have identified potential adverse reactions of a commonly used multiple sclerosis drug.

Genetic variation linked to drug-induced liver damage in some patients

February 22, 2017
Scientists have discovered an uncommon genetic variation that may identify patients with a higher risk of liver damage associated with a range of commonly-prescribed medications.

Fatality rates are high within two years of drug-induced liver injury

June 26, 2017
Most patients suffering liver toxicity due to medications or herbal or dietary supplements recover from the acute liver injury without long-term problems, but some do not survive the injury or they require liver transplantation. ...

Understanding vitamin D trends in children with non-alcoholic fatty liver disease

May 15, 2018
New research charts vitamin D levels and variations in genes that determine vitamin D status in UK children diagnosed with non-alcoholic fatty liver disease.

Recommended for you

Officials remove special rules for gene therapy experiments

August 16, 2018
U.S. health officials are eliminating special regulations for gene therapy experiments, saying that what was once exotic science is quickly becoming an established form of medical care with no extraordinary risks.

Genetic link discovered between circadian rhythms and mood disorders

August 15, 2018
Circadian rhythms are regular 24-hour variations in behaviour and activity that control many aspects of our lives, from hormone levels to sleeping and eating habits.

Ovarian cancer genetics unravelled

August 14, 2018
Patterns of genetic mutation in ovarian cancer are helping make sense of the disease, and could be used to personalise treatment in future.

New genome-editing strategy could lead to therapeutics

August 14, 2018
Researchers at UMass Medical School have developed a genome-editing strategy to correct disease-causing DNA mutations in mouse models of human genetic diseases, according to research published in the Aug. 18 edition of Nature ...

Study reveals broad 'genetic architectures' of traits and diseases

August 13, 2018
Scientists at Johns Hopkins Bloomberg School of Public Health have developed a powerful method for characterizing the broad patterns of genetic contributions to traits and diseases. The new method provides a "big picture" ...

Genetic tools uncover cause of childhood seizure disorder missed by other methods

August 13, 2018
Early childhood seizures result from a rare disease that begin in the first months of life. Researchers at University of Utah Health have developed high-tech tools to uncover the genetic cause of the most difficult to diagnose ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.